About AkaRx
AkaRx is a Healthcare company based in Paramus (United States) founded in 2005, and was acquired by Eisai in January 2010. Limited information available. Its focus areas include Biopharma Outsourcing, Diversified and Small Molecules & Peptides. Its competitors include Pfizer, LabConnect and Matchpoint Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
AkaRx, founded in 2005 in Paramus, United States, focuses on providing healthcare solutions, biopharma outsourcing, diversified, and small molecules peptides. Limited information available. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Investors in AkaRx
AkaRx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Eisai.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drugs for oncology and neurological disorders are developed by Eisai. | 1941 | eisai.com | Tokyo, Japan |
Investor details for AkaRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of AkaRx
2 dated milestones of AkaRx across 5 years, from founding to its latest funding, stage changes and deals.
- Founded AkaRx is founded.
- Exit Acquired by Eisai.
Competitors of AkaRx
AkaRx has 3 listed competitors in our database, 3 of them funded. They include Pfizer, LabConnect and Matchpoint Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pfizer.com | 1849 | New York, United States | $8M | Pharmaceutical products for treating multiple diseases are provided. | ||
| labconnect.com | 2002 | Johnson, United States | $28.5M | Laboratory testing, clinical trial research, and biopharma services are provided. | ||
| matchpointtx.com | 2021 | Cambridge, United States | $100M | 27 | Small molecule medicine development and analytics services are provided. |
Detailed competitors of AkaRx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as AkaRx (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AkaRx
AkaRx was founded in 2005.
AkaRx is headquartered in Paramus, United States. It is registered at Paramus, New Jersey, United States.
AkaRx, founded in 2005 in Paramus, United States, focuses on providing healthcare solutions, biopharma outsourcing, diversified, and small molecules peptides. Limited information available. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
AkaRx's top competitors include Pfizer, LabConnect and Matchpoint Therapeutics.
AkaRx has 1 investor. Key investors include Eisai.
Yes. AkaRx was acquired by Eisai in January 2010.